Biomarker ID | 1560 |
PMID | 9563891 |
Year | 1998 |
Biomarker | Versican |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | RR: 7.66 (95% CI: 2.53-23.18) |
Effect on Pathways | Pathway include: Chondroitin sulfate/dermatan sulfate metabolism; Integrin Pathway; ERK Signaling; Glycosaminoglycan metabolism; Phospholipase-C Pathway |
Experiment | Progression Vs No Progression |
Type of Biomarker | Prognostic |
Cohort | 11 men with no history of prostate cancer were selected along with 43 men with prostate cancer |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0003 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |